Eli Lilly and Co.’s (LLY) cardiovascular franchise includes two drugs—Cialis and Effient. These drugs comprise ~15.0% of the company’s total revenues. The chart below shows the revenues of its cardiovascular drugs since 3Q15.
Cialis is a blockbuster drug used for the treatment of erectile dysfunction and benign prostatic hyperplasia. Cialis’s sales totaled $627.3 million during 2Q17, which was nearly flat compared to its 2Q16 revenues of $630.5 million.
The company’s Cialis sales include a 1.0% decrease following strong competition in the US markets. Its international sales were nearly flat due to the lower sales and the negative impact of foreign exchange, offset by the higher realized prices in international markets.
Effient is an antiplatelet drug that is used in combination with aspirin for the prevention of blood clots in arteries and stents. This indication is used to reduce the chances of heart-related events for patients with acute coronary syndrome. Effient’s sales totaled $142.9 million during 2Q17, a 6.0% increase compared to its 2Q16 revenues of $135.1 million.
Adcirca and Reopro
Eli Lilly’s (LLY) other drugs in the cardiovascular franchise include Adcirca and Reopro. Adcirca, an oral treatment for pulmonary arterial hypertension, reported sales of $22.8 million in 2Q17. Reopro reported sales of $2.6 million during 2Q17.
To divest company-specific risks, investors can consider the SPDR S&P Pharmaceuticals ETF (XPH), which holds 4.3% of its total assets in Eli Lilly (LLY). XPH also holds 4.4% in Merck & Co. (MRK), 4.9% in Perrigo (PRGO), and 4.3% in Allergan Plc (AGN).